Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Merck & Co. Inc.
Headquarters: Rahway, NJ, United States of America
Website: https://www.merck.com/
Year Founded: 1891
Status: Public
Industry Sector: HealthTechnology
CEO: Robert M. Davis, MBA
Number Of Employees: 75,000
Enterprise Value: $277,342,680,000
PE Ratio: 13.01
Exchange/Ticker 1: NYSE:MRK
Exchange/Ticker 2: N/A
Latest Market Cap: $222,569,398,272
BioCentury | Mar 27, 2025
Data Byte
Immunology takeouts led by IgA nephropathy, IBD
Seven of 11 $1B+ immunology acquisitions focused on two diseases
BioCentury | Mar 26, 2025
Management Tracks
FDA names Barclay Butler COO
Plus: Scott Gottlieb named chair of Illumina, and updates from Syncromune and OSR
BioCentury | Mar 26, 2025
Finance
Early lessons from the NewCo Model
Panelists on a Capital Markets Preview webinar from BioCentury and Oppenheimer debate the hottest trend in dealmaking
BioCentury | Mar 26, 2025
Data Byte
China deals look beyond cancer
At least eight East-to-West licensing deals outside oncology so far this year
BioCentury | Mar 17, 2025
Finance
With Medicxi’s backing, Curevo takes aim at Shingrix with $110M series B
Former GSK vaccines head Slaoui becomes chairman as Seattle start-up advances shingles shot that may confer tolerability benefit
BioCentury | Mar 7, 2025
Finance
Strategics back Trimtech’s protein cluster degraders with $31M: Finance Report
Pharma venture arms join founding investors CIC, DDF to back U.K. start-up; plus venture rounds for Garuda, Ataraxis and Callio, and Tenaya’s follow-on
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Feb 28, 2025
Finance
Eikon draws $350M private round, holding off on public markets
Plus BridgeBio cancer subsidiary finds SPAC route to market, in an otherwise sleepy week for fundraising
BioCentury | Feb 25, 2025
Deals
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report
Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
BioCentury | Feb 25, 2025
Politics, Policy & Law
Trump warning to pharma CEOs comes as president rebuffs quick pill penalty fix
President Trump reiterates anger that U.S. pays more for drugs than other countries, says tariffs will spur domestic drug manufacturing
Items per page:
1 - 10 of 10927